Imcyse Announces Completion of Enrollment in Phase 2 IMPACT

Exceeded target enrollment with 110 patients randomized across 28 clinical sites in Europe, the United States and AustraliaEfficacy proof-of-concept data from IMPACT is expected in Q1 2024. Following

Related Keywords

Australia , Walloon Region , Waals Gewest , Belgium , Leuven , Region Flamande , United States , Lithuania , Dennis Riedl , Denis Bedoret , Anne Hennecke Julia Bittner , Jean Van Rampelbergh , Chuck Padala , Mc Services , European Commission , Innovative Medicines Initiative , Clinical Development , Catholic University Of Leuven , Van Rampelbergh , United Kingdom , Chantal Mathieu Principal Investigator , Multiple Sclerosis , Catholic University , Media Inquiries , Imcyse , Nnounces , Completion , Enrollment , Hase , Impact , Trial , Vdmcy , 098 , Type , Diabetes ,